Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: Systematic review and meta-analysis

Abstract

Purpose:

Intravitreal ranibizumab (RNB) and dexamethasone intravitreal implant (DII) were developed in the recent past and has been widely used for macular edema secondary to BRVO. We aimed to assess the efficacy and safety of intravitreal ranibizumab (RNB) compared to dexamethasone intravitreal implant (DII) in patients with macular edema secondary to branch retinal vein occlusion (BRVO).

Methods:

We performed a comprehensive search on topics that assess RNB and DII in patients with macular edema secondary to BRVO from several electronic databases.

Results:

There were 678 subjects from five studies. Ranibizumab was associated with a greater increase in best-corrected visual acuity (BCVA; mean difference 9.13, I²: 0%) compared to DII. Ranibizumab also demonstrated a greater ⩾10 (OR 2.76, I²: 0%) and ⩾15 letters (OR 2.78, I²: 0%) gain. RNB has better BCVA (logMAR scale) improvement at 6 months’ follow up (mean difference −0.15, I²: 64%) in favor of RNB. Higher IOP was found in DII group on follow-up (mean difference −2.92, I²: 89%) and RNB has lesser IOP ⩾10 mmHg increase compared to DII (OR 0.08, I²: 0%). Cataract formation and/or progression was less in RNB (OR 0.53, I²: 75%). The need for rescue laser was similar the two groups.

Conclusion:

Intravitreal RNB was more effective with less pronounced effect on IOP and cataract formation and/or progression compared to DII for patients with macular edema secondary to BRVO.

Keywords

Intravitreal ranibizumab dexamethasone macular edema branch retinal vein occlusion

Get full access to this article

View all access options for this article.

References

Baptiste

Lam

W-C

Albiani

, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 2015; 9: 1255–1268.

Rogers

McIntosh

Cheung

, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313–319.e1.

David

Zangwill

Badarna

, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197(2): 69–74.

Ota

Tsujikawa

Murakami

, et al. Subfoveal serous retinal detachment associated with extramacular branch retinal vein occlusion. Clin Ophthalmol 2013; 7: 237–241.

Flammer

Konieczka

Retinal venous pressure: the role of endothelin. EPMA J 2015; 6(1): 21.

Jaulim

Ahmed

Khanam

, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013; 33(5): 901–910.

Noma

Mimura

Eguchi

Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol 2013; 131(2): 160–165.

Finkelstein

Ischemic macular edema recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992; 110(10): 1427–1434.

Haller

Bandello

Belfort

, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134–1146.e3.

10.

Haller

Bandello

Belfort

, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 2011; 118(12): 2453–2460.

11.

Brown

Campochiaro

Bhisitkul

, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118(8): 1594–1602.

12.

Yuksel

Karti

Celik

, et al. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion. Clin Exp Optom 2018; 101(1): 116–122.

13.

Hattenbach

Feltgen

Bertelmann

, et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol 2018; 96(1): e10–e18.

14.

Bandello

Augustin

Tufail

, et al. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol 2018; 28(6): 697–705.

15.

Kumar

Sharma

Chandra

, et al. Comparison of the safety and efficacy of intravitreal ranibizumab with or without laser photocoagulation versus dexamethasone intravitreal implant with or without laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Folia Med (Plovdiv) 2019; 61(2): 240–248.

16.

Ozkaya

Tarakcioglu

Tanir

Ranibizumab versus dexamethasone implant in macular edema secondary to branch retinal vein occlusion: two-year outcomes. Optom Vis Sci 2018; 95(12): 1149–1154.

17.

Campochiaro

Heier

Feiner

, et al. Ranibizumab for macular edema following branch retinal vein occlusion. Ophthalmology 2010; 117(6): 1102–1112.e1.

18.

Noma

Funatsu

Yamasaki

, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140(2): 256.e1–256.e7.

19.

Ozaki

Hayashi

Vinores

, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64(4): 505–517.

20.

Dickerson

Steely

English-Wright

, et al. The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells. Exp Eye Res 1998; 66(6): 731–738.

21.

Johnson

Bradley

JMB

Acott

TS.

The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Investig Ophthalmol Vis Sci 1990; 31(12): 2568–2571.

22.

Singh

Ahmad

Yeh

, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004; 138(2): 286–287.

23.

Dot

El Chehab

Russo

, et al. Hypertonie oculaire après injections intra-vitréennes de corticoïdes, actualisation des connaissances en 2015. J Fr Ophtalmol 2015; 38(7): 656–664.

24.

Callanan

Loewenstein

Patel

, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe’s Arch Clin Exp Ophthalmol 2017; 255(3): 463–473.

25.

Sharma

Kuppermann

Bandello

, et al. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations – GEODEX-IOP study. Eye 2020; 34(6): 1063–1068.

26.

Moisseiev

Goldstein

Waisbourd

, et al. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye 2013; 27(1): 65–71.

27.

Cho

Choi

Lee

, et al. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study. BMJ Open 2019; 9(9): e030930.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB